Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
复制标题
大肠杆菌蛋白和多粘蛋白B的药代动力学/药效学B:我们在那里吗?
DOI:
10.1016/j.ijantimicag.2016.09.010
复制
发表时间:
2016-12
影响因子:
10.8
通讯作者:
Li J
中科院分区:
文献类型:
--
作者:
Tran TB;Velkov T;Nation RL;Forrest A;Tsuji BT;Bergen PJ;Li J
The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-line option for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria. Despite having similar structures and antibacterial activity in vitro, the two clinically available polymyxins have very different pharmacological properties, as colistin (polymyxin E) is intravenously administered to patients in the form of an inactive prodrug colistin methanesulphonate (sodium). This review will discuss recent progress in the pharmacokinetics/pharmacodynamics and toxicity of colistin and PMB, the factors that affect their pharmacological profiles, and the challenges for the effective use of both polymyxins. Strategies are proposed for optimising their clinical utility based upon the recent pharmacological studies in vitro, in animals and patients. In the ‘bad bugs, no drugs’ era, polymyxins are a critically important component of the antibiotic armamentarium against difficult-to-treat Gram-negative ‘superbugs’. Rational approaches to the use of polymyxins must be pursued to increase their effectiveness and to minimise resistance and toxicity.
登录
查看更多内容
影响因子:
4.9
作者:
Karaiskos, Ilias;Friberg, Lena E.;Giamarellou, Helen
通讯作者:
Giamarellou, Helen
影响因子:
28.2
作者:
Kubin, Christine J.;Ellman, Tanya M.;Yin, Michael T.
通讯作者:
Yin, Michael T.
影响因子:
5.2
作者:
Cheah, Soon-Ee;Wang, Jiping;Nation, Roger L.
通讯作者:
Nation, Roger L.
影响因子:
4.9
作者:
Li, J;Milne, RW;Coulthard, K
通讯作者:
Coulthard, K
影响因子:
4.9
作者:
Karvanen, Matti;Plachouras, Diamantis;Giamarellou, Helen
通讯作者:
Giamarellou, Helen